Malin Deon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Operator Good morning, ladies and gentlemen, and welcome to the Jounce Therapeutics First Quarter 2021 Earnings Conference Call. [Operator Instructions]. I will now turn the call over to your host, Malin Deon with Jounce Therapeutics. Please go ahead. Malin Deon -- Manager, Investor Relations & Corporate Communications Thank you, operator. Good morning, and welcome to the Jounce Therapeutics first quarter conference call. This morning we issued a press release which outlines the topics that we plan to discuss today. The release is available in the Investors and Media section of our website a...

Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has priced an underwritten public offering of 5,000,000 shares of common stock at a public offering price of $11.25 per share, which would result in gross proceeds of approximately $56.25 million, before underwriting discounts and commissions. The proceeds of the of...

Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results – Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 – – Ended 2020 with $213.2 million in cash, cash equivalents and investments – – Company to host conference call and webcast today at 8:00 AM ET – CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predi...